Intensifying government scrutiny suggests that prescribers pay close attention to licensing board, payer and professional society guidance on ordering and using drug tests when treatment involves opioid therapy. Attorney Bolen sketches the changing regulatory landscape and how prescribers should appropriately respond and prepare.
Did you enjoy this article?
Subscribe to the PAINWeek Newsletter
and get our latest articles and more direct to your inbox